GlassScriptPhysician profile
Mylisa Moses
NPI 1265939565
$2,594.67
in general payments reported to CMS, 2019-2025
21 companies · $774 in 2025
The $774 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.03 · 2022: $103 · 2023: $468 · 2024: $1,227 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.56 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $349.87 | 2023-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $255.62 | 2022-2025 | |
| Lilly USA, LLC | $224.39 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $215.58 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $210.06 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $131.89 | 2024-2025 | |
| Abbvie INC. | $119.83 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.36 | 2022-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $89.15 | 2023-2024 | Nexletol |
| Astellas Pharma US INC | $61.32 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $55.91 | 2024-2025 | Cologuard Collection Kit |
| Verity Pharmaceuticals INC. | $53.85 | 2024-2025 | Tlando |
| Sumitomo Pharma America, INC. | $38.40 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $29.47 | 2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $27.06 | 2023 | Axonics |
| Horizon Therapeutics Plc | $20.47 | 2023 | Krystexxa |
| Abbott Laboratories | $20.36 | 2024 | Freestyle Libre 3 |
| Tris Pharma INC | $14.79 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $14.07 | 2024 | Capvaxive |
| Currax Pharmaceuticals LLC | $13.66 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mylisa Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.